Topiramate’s effectiveness on weight reduction and metabolic syndrome in obese patients with schizophrenia and schizoaffective

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210622051665N1

Enrollment

Registered

2021-07-25

Start date

2020-01-21

Completion date

Unknown

Last updated

2021-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia,Schizoaffective.

Interventions

Intervention 1: Patients were randomly divided (in alphabetical order) into two groups of men and women, and each of these groups was divided into intervention and control groups. A total of 33 patien

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Age between 18 to 65 years BMI above 27 Patients with schizophrenia or schizoaffective disorder receiving a second-generation antipsychotic drug Obtaining informed consent from the patient and the patient's legal guardian

Exclusion criteria

Exclusion criteria: Diabetis Pregnancy or breastfeeding Patients with heart failure Patients with kidney disease Hypersensitivity to topiramate

Design outcomes

Primary

Measure	Time frame
BMI>27. Timepoint: before study and in weeks 4,8 and 12. Method of measurement: measure height and weight.;Measure abdominal circumference. Timepoint: before study and in weeks 4,8 and 12. Method of measurement: Tape meter.;FBS. Timepoint: before the study and in weeks 4,8 and 12. Method of measurement: Blood sample and lab result.;Total cholesterol. Timepoint: before the study and in weeks 4,8 and 12. Method of measurement: Blood sample and lab result.;Triglyceride. Timepoint: before the study and in weeks 4,8 and 12. Method of measurement: Blood sample and lab result.	—

Measure

Time frame

BMI>27. Timepoint: before study and in weeks 4,8 and 12. Method of measurement: measure height and weight.;Measure abdominal circumference. Timepoint: before study and in weeks 4,8 and 12. Method of measurement: Tape meter.;FBS. Timepoint: before the study and in weeks 4,8 and 12. Method of measurement: Blood sample and lab result.;Total cholesterol. Timepoint: before the study and in weeks 4,8 and 12. Method of measurement: Blood sample and lab result.;Triglyceride. Timepoint: before the study and in weeks 4,8 and 12. Method of measurement: Blood sample and lab result.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHamidreza Kamravan

University of social welfare and rehabilitation sciences

kamravan@gmail.com+98 21 6683 4793

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026